Latest News and Events
Filter by
Selections
April 4, 2023
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Read MoreMarch 31, 2023
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreMarch 3, 2023
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
Read MoreFebruary 28, 2023
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreFebruary 15, 2023